MiroBio develops a novel class of therapeutic agents designed to treat autoimmune diseases by modulating immune responses
MiroBio develops a novel class of therapeutic agents designed to treat autoimmune diseases by modulating immune responses. The company focuses on creating agonists of immune inhibitory receptors, such as B- and T-Lymphocyte Attenuator (BTLA) and PD-1, to restore immune balance.